A5018230264- Multiple Myeloma Research and Treatments
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Peptidase Inhibition and Analysis
- Blood Coagulation and Thrombosis Mechanisms
- Cancer-related gene regulation
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Cancer Risks and Factors
- Cancer Treatment and Pharmacology
- Inflammatory Myopathies and Dermatomyositis
- Immunodeficiency and Autoimmune Disorders
- Vascular Anomalies and Treatments
- Hematopoietic Stem Cell Transplantation
- Otitis Media and Relapsing Polychondritis
- Monoclonal and Polyclonal Antibodies Research
- Blood groups and transfusion
University Hospital Carl Gustav Carus
2018-2025
TU Dresden
2015-2025
Klinik und Poliklinik für Psychotherapie und Psychosomatik
2016-2024
Technical University of Munich
2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.In investigator-sponsored randomized phase II NIVAHL trial early-stage unfavorable classical Hodgkin lymphoma (HL),...
Abstract The VEXAS syndrome, a genetically defined autoimmune disease, associated with various hematological neoplasms has been attracting growing attention since its initial description in 2020. While therapeutic strategies have explored case studies, the optimal treatment strategy is still under investigation and allogeneic cell transplantation considered only curative treatment. Here, we describe 2 patients who achieved complete molecular remission of underlying UBA1 mutant clone outside...
Inflammation plays an important role in chimeric antigen receptor (CAR) T-cell therapy, especially the pathophysiology of cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS). Clonal hematopoiesis indetermined potential (CHIP) has also been associated with chronic inflammation. The relevance CHIP context CAR treatment is widely unknown. We evaluated prevalence CHIP, using a targeted deep sequencing approach, cohort patients relapsed/refractory (r/r)...
BackgroundAcquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) standard of care to eradicate autoantibody production and protect from further but carries a risk severe infection mortality in frail patients with AHA. Recently, emicizumab has been studied for its potential reduce the need early aggressive IST.ObjectivesTo compare outcomes 2 studies that used either IST (GTH-AH 01/2010;...
Abstract Objective This study evaluated the legibility, comprehension, and clinical usability of visual timelines for communicating cancer treatment paths. We examined how these aids enhance participants’ patients’ understanding their plans. Materials Methods The included 2 online surveys 1 in-person survey with hematology patients. involved 306 160 participants, respectively, while evaluation 30 patients (11 re-surveyed) 24 medical doctors. Participants were assessed on ability to...
A 28-year-old man underwent FDG-PET/CT for Hodgkin lymphoma restaging after 6 cycles of BEACOPP chemotherapy. He had recently been diagnosed with herpes zoster, treated antivirals, presenting a painful rash on the right lower flank. The FDG PET scan revealed high focal uptake in 11th spinal nerve ganglion and moderate diffuse area. follow-up 10 weeks showed complete regression both findings. To best our knowledge, this is first reported case marked FDG-avid indicating active ganglioneuritis...
Abstract For patients (pts) with relapsed or refractory multiple myeloma (RRMM) after previous autologous hematopoietic cell transplantation (AHCT), novel agents, cellular and immunotherapies are increasingly available. Options for second-line treatment mostly include triplet regimens based on proteasome inhibitors, immunomodulatory drugs anti-CD38 monoclonal antibodies since recently also CAR T cells. The importance of salvage (retransplantation, Re-AHCT) has significantly decreased in...
Abstract Purpose: A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high interim complete response rates to nivolumab-based first-line treatment in early-stage unfavorable Hodgkin lymphoma. However, biomarkers such as metabolic tumor volume (MTV) or total lesion glycolysis (TLG) and their change under (ΔMTV ΔTLG), measured on PET, might provide additional relevant information for assessment this setting. Hence, current aimed investigate early checkpoint inhibitor...
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted a significant increase minimal residual disease negativity (MRD-) rates after induction therapy. A total 662 were randomly assigned receive therapy Isa-RVd (n = 331) or RVd 329), followed by single tandem autologous stem-cell transplant and second...
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Standard treatment consists of control with bypassing agents and immunosuppressive therapy. Emicizumab bispecific antibody that mimics the function activated FVIII irrespective presence neutralizing antibodies. Recently, GTH-AHA-EMI study demonstrated emicizumab prevents bleeds allows to postpone immunosuppression, which may influence future strategies.
8000 Background: In medically fit patients with newly diagnosed (ND) multiple myeloma (MM), triplet or quadruplet induction regimens, high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) remain a standard of care. Carfilzomib (K), lenalidomide (R) dexamethasone (d, KRd) induction/consolidation has proven exceptionally effective. Elotuzumab (E), an anti-SLAMF-7 monoclonal antibody bears favorable tolerability in relapsed/refractory MM while its role NDMM remains unclear....
Von Willebrand disease (VWD), the most prevalent hereditary bleeding disorder, results from deficiency of von factor (VWF).
Abstract Acquired von Willebrand disease (aVWD) is frequently observed in patients with the need for extracorporeal membrane oxygenation (ECMO). aVWD can be treated by plasma-derived concentrates containing factor VIII (FVIII) and/or (VWF) and recombinant VWF concentrate as well adjuvant therapies such tranexamic acid desmopressin. However, all of these therapeutic options possibly cause thromboembolism. Therefore, optimal treatment remains uncertain. This report presents a case 16-year-old...